+1 (629)348-3199An immuno-genomic atlas for cancer immunotherapy response
18th International Conference on CANCER AND CANCER THERAPY
June 13-14, 2022 | Webinar
Qi Liu, Jing Yang and Yu Shyr
Vanderbilt University Medical Center, USA
Scientific Tracks Abstracts : J Clin Oncol Cancer Res
Abstract:
An increasing number of studies on cancer immunotherapy have generated a huge amount of omics data and provided an unprecedented opportunity to identify response-related genomic signatures. However, those valuable datasets are not easily accessible to the research community. We established Cancer-Immu a comprehensive portal that connects large-scale multidimensional omics data with immunotherapy responses. Currently, Cancer-Immu has collected 3,652 patients for 16 cancer types, which provides a great resource for the discovery and validation of novel signatures predictive of response. Meta-analysis of 3,652 patients and single-cell RNA-seq highlights the importance of circuits between macrophage and T cells in immunotherapy sensitivity. Recent Publications 1. Qi Liu, et.al, (2022): Interaction of lncRNA MIR100HG with hnRNPA2B1 facilitates m6A-dependent stabilization of TCF7L2 mRNA and colorectal cancer progression. Molecular Cancer 21 (1), 1-18 2. Qi Liu, et.al, (2022): Dysregulated Ligand-receptor interactions from single cell transcriptomics. Bioinformatics, 1–6. 3. Qi Liu, et.al, (2022): VAP-A and its binding partner CERT drive biogenesis of RNA-containing extracellular vesicles at ER membrane contact sites. Developmental Cell 57 (8), 974-994.
Biography:
Qi Liu is an Associate Professor and Director of the Omics Coordinating Center at Vanderbilt University Medical Center for Quantitative Sciences, USA. She completed her PhD from Shanghai Jiaotong University, China in 2003. She has over 150 publications that have been cited over 7000 times, and her publication H-index is 36 and has been serving as an editorial board member of reputed Journals.
PDF HTML